Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Neostigmine Clear all
Completed Phase 4 Interventional Results available

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

NCT06112353
View directory record Official record
Conditions
Intestinal Disease
Interventions
Neostigmine Injectable Solution, Sugammadex injection
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

NCT03346070
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Best Management of Muscle Relaxation- Objective Monitoring

NCT03958201
View directory record Official record
Conditions
Residual Paralysis, Post Anesthesia
Interventions
Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 17, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

NCT05116930
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Neostigmine, Glycopyrrolate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex as Rescue Therapy

NCT05661409
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

NCT03543826
View directory record Official record
Conditions
Muscle Weakness
Interventions
Protocol for rocuronium neuromuscular block
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications

NCT02861131
View directory record Official record
Conditions
Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
70 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage

NCT00745095
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Neostigmine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

NCT03923556
View directory record Official record
Conditions
Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

NCT03111121
View directory record Official record
Conditions
Microlaryngoscopy, Rigid Bronchoscopy
Interventions
Sugammadex, neostigmine, glycopyrrolate
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 17, 2026, 10:10 PM EDT
Active, not recruiting Phase 3 Interventional

Neostigmine and Glycopyrrolate by Iontophoresis

NCT06351995
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Transdermal Administration by a Novel Wireless Iontophoresis Device

NCT06351852
View directory record Official record
Conditions
Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions
Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics
Drug · Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

NCT03112993
View directory record Official record
Conditions
Spine Surgery
Interventions
sugammadex, Neostigmine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 17, 2026, 10:10 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Residual Neuromuscular Blockade in Cardiac Surgery Patients

NCT03574337
View directory record Official record
Conditions
Residual Neuromuscular Blockade
Interventions
Sugammadex, neostigmine/glycopyrolate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 17, 2026, 10:10 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Comparison of Sugammadex and Neostigmine During PACU Stay

NCT04096144
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Neuromuscular Blocking Agents
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

NCT03168308
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine w/ Glycopyrrolate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI

NCT00855283
View directory record Official record
Conditions
SCI
Interventions
IN NEO, IN NEO + IN Glycopyrrolate, IV Visit
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05794503
View directory record Official record
Conditions
Urinary Retention Postoperative, Laparoscopic Cholecystectomy, Neuromuscular Blockade, Sugammadex, Neostigmine, Neuromuscular Blocking Agents, Physiological Effects of Drugs
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Sugammadex in Outpatient Urological Procedures

NCT03138967
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Interventions
Rocuronium, Sugammadex, Neostigmine, Glycopyrrolate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

NCT03579589
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex vs Neostigmine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex To IMprove Bowel Function

NCT04546672
View directory record Official record
Conditions
Bowel Dysfunction, Postoperative Complications, Neuromuscular Blockade
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 17, 2026, 10:10 PM EDT